FDA Approves RINVOQ — AbbVie Inc.

AbbVie Inc. received final regulatory approval on August 16, 2019, for Upadacitinib, expanding its gastrointestinal pharmacopoeia under the RINVOQ brand. The oral therapy is projected to diversify AbbVie’s growth pipeline and intensify its competitive standing within the acute and chronic gastrointestinal markets.